Modality
Bispecific Ab
MOA
KRASG12Di
Target
WRN
Pathway
Sphingolipid
FTDRSV
Development Pipeline
Preclinical
~Oct 2014
→ ~Jan 2016
Phase 1
~Apr 2016
→ ~Jul 2017
Phase 2
~Oct 2017
→ ~Jan 2019
Phase 3
Apr 2019
→ Mar 2028
Phase 3Current
NCT03714313
447 pts·RSV
2019-04→TBD·Not yet recruiting
NCT06715252
1,332 pts·FTD
2019-05→2028-03·Recruiting
NCT04921031
2,265 pts·FTD
2023-04→TBD·Active
4,044 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-03-061.9y awayPh3 Readout· FTD
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P3
Not yet…
P3
Recruit…
P3
Active
Catalysts
Ph3 Readout
2028-03-06 · 1.9y away
FTD
RecruitingActiveNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03714313 | Phase 3 | RSV | Not yet recr... | 447 | EASI-75 |
| NCT06715252 | Phase 3 | FTD | Recruiting | 1332 | NT-proBNP |
| NCT04921031 | Phase 3 | FTD | Active | 2265 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα |